Csp Exam Test Questions & Answers 2023 ( A+ Graded 100% Verified)

Which of the following recommendations would be most appropriate when discussing a change in therapy from Exjade (deferasirox) to Jadenu (deferasirox) with a healthcare provider? a. There is no need to monitor renal function with Jadenu b. The Jadenu dose should be started at a dosage 30% less than current Exjade dose c. Dosing is based on equivalent mg/kg dosing parameters d. The Jadenu dose should be started at a dosage 30% more than current Exjade dose {Ans: b. The Jadenu dose should be started at a dosage 30% less than current Exjade dose}Which of the following tyrosine kinase inhibitors have a black box warning for arterial thrombosis? a. Sprycel (dasatinib) b. Iclusig (ponatinib) c. Bosulif (bosutinib) d. Gleevec (imatinib) e. Tasigna (nilotinib) {Ans: b. Iclusig (ponatinib)}All of the medications below can be stored for 30 days at room temperature except: a. Plegridy (peginterferon beta‐1a) b. Avonex (interferon beta‐1a) c. Rebif (interferon beta‐1a) d. Betaseron (interferon beta‐1b) {Ans: b. Avonex (interferon beta‐1a)}A patient in your clinic has a new diagnosis of chronic phase Philadelphia chromosome positive CML and the provider wants to order treatment with Tasigna (nilotinib). During your drug review, you notice the patient is on